drugset / Trial / NCT05372003

IL-4 and Insulin Resistance for Treatment of Patients With Atopic Dermatitis

NCT05372003

Phase 0 Completed 7 enrolled Mayo Clinic
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to better understand the interactions between the innate immune system, in particular eosinophils, their secreted cytokines (interleukin-4), and metabolism in human health and disease states such as obesity and insulin resistance.

Timeline

Start
2022-08-09
Primary completion
2024-02-23
Completion
2024-02-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Dupilumab Monoclonal antibody

Indications